Microsoft shares jump after fourth-quarter earnings beat on AI-fueled cloud growth
Guy Archibald Innes, a director at VolitionRx Ltd (NYSE:VNRX), has acquired 20,000 shares of the company’s common stock, according to a recent SEC filing. The shares were purchased at a price of $0.5386 each, totaling $10,772. The purchase comes as the stock has shown strength with a 9.6% gain over the past week, though trading near its 52-week low of $0.40. Following this transaction, Innes directly owns 888,689 shares. Additionally, he has indirect ownership of shares through various trusts and family members, including The Innes Family Bare Trust 2023 and The Dill Faulkes Educational Trust Limited. While the company faces challenges with cash burn and profitability according to InvestingPro analysis, analyst targets suggest significant upside potential, with price targets ranging from $2 to $5 per share.
In other recent news, VolitionRx Limited reported its first-quarter 2025 financial results, which showed a larger-than-expected loss per share and revenue shortfall compared to analyst forecasts. The company posted an earnings per share of -$0.06, missing the projected -$0.04, while revenue was $250,000, significantly below the expected $1.31 million. Despite these challenges, VolitionRx is actively working to commercialize its Nu.Q platform and has reduced operational expenses by 35% from the previous year. The company is also pursuing multiple human licensing agreements and expects to double its Nu.Q Discover revenue.
Benchmark analysts maintained a Hold rating on VolitionRx, noting the company’s focus on leveraging its nucleosomic testing technology through 2025. VolitionRx aims to secure a licensing agreement with a major in vitro diagnostics firm and expand its veterinary testing division. The company anticipates milestone payments tied to the success of its licensing and product development objectives. Investors and analysts are closely monitoring VolitionRx’s progress as it seeks to capitalize on its technological advancements while managing financial and operational challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.